September 2011

Novartis Obtains Defense Verdict in Jury Trial Against Bisphosphonate Claims

United States - Kentucky

FaegreBD's trial team obtained a defense verdict for firm client Novartis in a jury trial in federal court in Bowling Green, Kentucky. Novartis manufactures and sells Zometa, a drug indicated to strengthen bone in cancer patients whose disease has metastasized to bone. The plaintiff, a woman suffering from metastatic breast cancer, alleged she developed a condition called osteonecrosis of the jaw (ONJ) as a result of consuming Zometa.

This was one of hundreds of similar cases against Novartis ongoing across the country. FaegreBD was retained to try this case after the company's national counsel had worked it up through discovery and most pre-trial motions. After a three-week trial, the jury returned a complete defense verdict. Mahaney v. Novartis Pharmaceuticals Corp., United States District Court, W.D. Kentucky, Case No. 1:06-CV-00035-R.

Faegre Baker Daniels 网站使用 Cookie 来提升您的浏览体验。